Coalition for Epidemic Preparedness Innovations

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Developer of immunity based vaccine intended to make it accessible across the globe. The company's vaccine are developed with the aim to prevent all the possible disease in the community and benefit every individual, enabling people to avail improved healthcare and avoid diseases.

NEC OncoImmunity AS is a bioinformatics company based in Oslo, Norway, specializing in the development of software solutions that leverage machine learning to predict immunogenic neoantigens for personalized cancer immunotherapy. Founded in 2014, the company aims to bridge significant knowledge gaps in identifying neoantigen targets that are critical for the creation of personalized cancer vaccines and cell therapies. Its proprietary software facilitates effective patient selection for cancer treatments by assessing individual characteristics such as HLA-binding and T cell reactivity. By providing tools that enable the discovery of neoantigen-based immunotherapies and biomarkers, NEC OncoImmunity supports the advancement of personalized medicine in oncology. The company operates as a subsidiary of NEC Corporation and is located at the Oslo Cancer Cluster Incubator.

Vaxxinity is a biotechnology company focused on the development of synthetic peptide vaccines to prevent and treat infectious diseases and chronic conditions. Utilizing its proprietary technology platform, Vaxxinity creates innovative, peptide-based active immunotherapy medicines that aim to transform the treatment landscape for chronic diseases, which are often dominated by expensive monoclonal antibodies. The company's approach enables the selective activation of various immune system components and targets specific pathogens with high precision. Vaxxinity's pipeline includes candidates designed to address conditions such as Alzheimer's, Parkinson's disease, migraines, and hypercholesterolemia, reflecting its commitment to improving global healthcare accessibility and efficiency.

DIOSyn Vax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines) is new technology that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.

MigVax Ltd. engages in the development, manufacture, and commercialization of vaccines for viruses in humans. It develops a vaccine against infectious bronchitis virus. The company is based in Kiryat Shmona, Israel. MigVax Ltd. operates as a subsidiary of MIGAL - Galilee Research Institute LTD.

Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan is a world leader in developing vaccines and technologies against infectious diseases.

Dynavax Technologies Corporation is a biopharmaceutical company headquartered in Emeryville, California, specializing in the discovery and development of novel vaccines and treatments for infectious diseases. The company markets HEPLISAV-B, an adjuvanted vaccine for the prevention of hepatitis B infection in adults. Dynavax utilizes its unique Toll-like Receptor Immune Modulation Platform to stimulate the body's immune responses, which is integral to its product development. In addition to its commercial offerings, Dynavax has an active immuno-oncology portfolio, featuring candidates such as SD-101 and DV281. The company is engaged in various research collaborations aimed at developing COVID-19 vaccines, partnering with organizations like Clover Biopharmaceuticals, the University of Queensland, and CEPI. These partnerships reflect Dynavax's commitment to addressing urgent health challenges through innovative vaccine solutions. Founded in 1996, Dynavax has evolved from its original name, Double Helix Corporation, to focus on enhancing immune responses for better disease prevention and treatment.

Bharat Biotech Ltd. is a biotechnology company based in Hyderabad, India, specializing in the research, development, and manufacture of vaccines and biotherapeutics. The company's product portfolio includes a range of vaccines such as Revac-B+, a recombinant hepatitis-B vaccine; TYPBAR, a typhoid vaccine; BIOPOLIO, a vaccine for poliomyelitis; INDIRAB, a rabies vaccine; and BioHib, a vaccine for haemophilus influenza type b. Additionally, Bharat Biotech produces various biotherapeutics, including gels for diabetic foot ulcers and burns, as well as injections for osteoarthritis and anticoagulation. The company also offers women's healthcare products, such as human chorionic gonadotrophin and menotropin, and has developed a cell culture H1N1 swine flu vaccine. Bharat Biotech exports its products to several countries, including Kenya, Zambia, and the Philippines. Established in 1996, the company has made significant contributions to public health through its innovative vaccine and therapeutic solutions.

Novavax, Inc. is a late-stage biotechnology company based in Gaithersburg, Maryland, that specializes in the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases. The company’s lead vaccine candidates include ResVax, designed to protect infants from respiratory syncytial virus (RSV) through maternal immunization, and NanoFlu, which targets seasonal influenza in older adults. Both of these candidates utilize the proprietary Matrix-M adjuvant to enhance immune responses. Novavax is also advancing a vaccine for RSV targeting older adults and children, as well as a candidate against the Ebola virus and a combination vaccine for influenza and RSV. Additionally, the company has initiated the development of a COVID-19 vaccine candidate, NVX-CoV2373, in collaboration with Takeda Pharmaceutical Company. Established in 1987, Novavax aims to address urgent global health needs through its innovative vaccine technologies.

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and preventing diseases associated with human papillomavirus (HPV), cancer, and various infectious diseases. The company's proprietary SynCon immunotherapy design enhances the immune response against cancerous cells and provides broad protection against multiple pathogens. Inovio is actively conducting clinical studies for its DNA medicines, particularly for HPV-related precancers and cancers, as well as other diseases such as glioblastoma, prostate cancer, HIV, and COVID-19. Its lead candidate, VGX-3100, is in Phase 3 trials for treating precancerous cervical dysplasia linked to high-risk HPV types. The company has established partnerships with various organizations, including major pharmaceutical companies and research institutions, to advance its research and development efforts. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals is recognized for its innovative approach to immunotherapy and gene therapy.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Novavax, Inc. is a late-stage biotechnology company based in Gaithersburg, Maryland, that specializes in the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases. The company’s lead vaccine candidates include ResVax, designed to protect infants from respiratory syncytial virus (RSV) through maternal immunization, and NanoFlu, which targets seasonal influenza in older adults. Both of these candidates utilize the proprietary Matrix-M adjuvant to enhance immune responses. Novavax is also advancing a vaccine for RSV targeting older adults and children, as well as a candidate against the Ebola virus and a combination vaccine for influenza and RSV. Additionally, the company has initiated the development of a COVID-19 vaccine candidate, NVX-CoV2373, in collaboration with Takeda Pharmaceutical Company. Established in 1987, Novavax aims to address urgent global health needs through its innovative vaccine technologies.

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and preventing diseases associated with human papillomavirus (HPV), cancer, and various infectious diseases. The company's proprietary SynCon immunotherapy design enhances the immune response against cancerous cells and provides broad protection against multiple pathogens. Inovio is actively conducting clinical studies for its DNA medicines, particularly for HPV-related precancers and cancers, as well as other diseases such as glioblastoma, prostate cancer, HIV, and COVID-19. Its lead candidate, VGX-3100, is in Phase 3 trials for treating precancerous cervical dysplasia linked to high-risk HPV types. The company has established partnerships with various organizations, including major pharmaceutical companies and research institutions, to advance its research and development efforts. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals is recognized for its innovative approach to immunotherapy and gene therapy.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.